Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter in the previous year, the business posted ($0.13) EPS. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Stock Up 0.4 %

Nautilus Biotechnology stock traded up $0.01 during trading on Tuesday, hitting $2.78. The stock had a trading volume of 253,881 shares, compared to its average volume of 75,225. The stock's 50 day moving average is $2.70 and its two-hundred day moving average is $2.61. Nautilus Biotechnology has a 1 year low of $2.19 and a 1 year high of $3.45. The stock has a market cap of $348.24 million, a price-to-earnings ratio of -5.05 and a beta of 1.22.

Insider Activity

In other Nautilus Biotechnology news, VP Mary E. Godwin sold 47,031 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $2.87, for a total transaction of $134,978.97. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 40.50% of the company's stock.

Analyst Ratings Changes

Separately, Guggenheim initiated coverage on Nautilus Biotechnology in a research report on Thursday, June 27th. They set a "buy" rating and a $6.00 price target on the stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.